Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Follow Up - CRFs Paliperidone Palmitate Schizophrenia NCT01515423

- 23.05.17 - 1 Formular, 9 Itemgruppen, 46 Datenelemente, 1 Sprache

Itemgruppen: Date of visit, Clinical Global Impression - Severity, Resource Use Questionnaire A Hospitalisation, Resource Use Questionnaire B Emergency room visits without hospitalisation, Resource Use Questionnaire C Day clinic, Resource Use Questionnaire D Night clinic, Resource Use Questionnaire E Outpatient treatment, Resource Use Questionnaire F Daily living, Resource Use Questionnaire G Productivity of subject

A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01515423 Sponsor: Janssen Research & Development, LLC Other drug name: TREVICTA®

Early Withdrawal Follow-Up GSK Rosiglitazone Alzheimer's disease 100468

- 25.07.17 - 1 Formular, 10 Itemgruppen, 15 Datenelemente, 1 Sprache

Itemgruppen: Central Laboratory Instructions, Visit Information, Investigator Instructions, Vital Signs, Central Laboratory, Concomitant Medication, Adverse Event, Physical Examination, Pedal Oedema, End of Study

Study ID: 100468 Clinical Study ID: AVA100468 Study Title: An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Avandia XR,Rosiglitazone XR,Avandia Study Indication: Alzheimer's Disease Early Withdrawal Follow-Up

Study End/ Follow Up GSK Rosiglitazone Alzheimer's disease 100468

- 25.07.17 - 1 Formular, 9 Itemgruppen, 14 Datenelemente, 1 Sprache

Itemgruppen: Central Laboratory Instructions, Visit Information, Investigator Instructions, Vital Signs, Central Laboratory, Concomitant Medication, Adverse Event, Physical Examination, Pedal Oedema

Study ID: 100468 Clinical Study ID: AVA100468 Study Title: An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Avandia XR,Rosiglitazone XR,Avandia Study Indication: Alzheimer's Disease Study End/ Follow Up

1 Year Follow up M102 Inventory of completed forms II (patient) MaAN NCT02962726

- 20.02.17 - 1 Formular, 1 Itemgruppe, 1 Datenelement, 1 Sprache

Itemgruppe: MAN_M102_INVENTORY_II_PAT

Event: 1 Year Follow up. Inventory of completed forms II (patient) form of the MaAN study (Microbiome Shifts in Adolescent Anorexia Nervosa) NCT02962726. The aim of this study is to evaluate the effect of starvation and recovery in adolescent anorexia nervosa patients in regard to microbiome activity and composition and to elucidate potential connections between weight gain, depression and other comorbidities, further to capture hormone levels and inflammation parameters in a longitudinal design. Publication granted by Prof. Deserno, UK Aachen. Inventar ausgefüllter Formulare II (Patient) Formular der MaAN Studie (Veränderungen des Mikrobioms bei adoleszenter Anorexia Nervosa) NCT02962726.

1 Year Follow up M042 Visit basis GI complaints and samples MaAN NCT02962726 - 1 Year Follow up M042 Visit basis GI complaints and samples MaAN NCT02962726

- 20.02.17 - 1 Formular, 3 Itemgruppen, 26 Datenelemente, 2 Sprachen

Itemgruppen: MAN_M042_BASE_VISIT, MAN_M042_GI_TROUBLE, MAN_M042_SAMPLES

Event: 1 Year Follow up. Visit basis, GI complaints and samples form of the MaAN study (Microbiome Shifts in Adolescent Anorexia Nervosa) NCT02962726. The aim of this study is to evaluate the effect of starvation and recovery in adolescent anorexia nervosa patients in regard to microbiome activity and composition and to elucidate potential connections between weight gain, depression and other comorbidities, further to capture hormone levels and inflammation parameters in a longitudinal design. Publication granted by Prof. Deserno, UK Aachen. Visitenbasis, GI-Beschwerden und Proben Formular der MaAN Studie (Veränderungen des Mikrobioms bei adoleszenter Anorexia Nervosa) NCT02962726.

1 Year Follow upM061 Blood values special blood values Patient MaAN NCT02962726 - 1 Year Follow up M061 Blood values special blood values MaAN NCT02962726

- 20.02.17 - 1 Formular, 1 Itemgruppe, 8 Datenelemente, 2 Sprachen

Itemgruppe: MAN_M061_BLOOD_PARTICULAR

Event: 1 Year Follow up. Blood values special blood values form of the MaAN study (Microbiome Shifts in Adolescent Anorexia Nervosa) NCT02962726. The aim of this study is to evaluate the effect of starvation and recovery in adolescent anorexia nervosa patients in regard to microbiome activity and composition and to elucidate potential connections between weight gain, depression and other comorbidities, further to capture hormone levels and inflammation parameters in a longitudinal design. Publication granted by Prof. Deserno, UK Aachen. Blutwerte spezielle Blutwerte Formular der MaAN Studie (Veränderungen des Mikrobioms bei adoleszenter Anorexia Nervosa) NCT02962726.

1 Year Follow up M101 Inventory of completed forms I Patient MaAN NCT02962726 - 1 Year Follow up M101 Inventory of completed forms I MaAN NCT02962726

- 20.02.17 - 1 Formular, 1 Itemgruppe, 3 Datenelemente, 1 Sprache

Itemgruppe: MAN_M101_INVENTORY_I

Event: 1 Year Follow up. Inventory of completed forms I form of the MaAN study (Microbiome Shifts in Adolescent Anorexia Nervosa) NCT02962726. The aim of this study is to evaluate the effect of starvation and recovery in adolescent anorexia nervosa patients in regard to microbiome activity and composition and to elucidate potential connections between weight gain, depression and other comorbidities, further to capture hormone levels and inflammation parameters in a longitudinal design. Publication granted by Prof. Deserno, UK Aachen. Inventar ausgefüllter Formulare I Formular der MaAN Studie (Veränderungen des Mikrobioms bei adoleszenter Anorexia Nervosa) NCT02962726.

1 Year Follow up M051 Blood value base and additional blood values Patient MaAN NCT02962726 - 1 Year Follow up M051 Blood value base and additional blood values MaAN NCT02962726

- 20.02.17 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 2 Sprachen

Itemgruppen: MAN_M051_BLOOD_BASE, MAN_M051_BLOOD_SUPPL

Event: 1 Year Follow up. Blood value base and additional blood values form of the MaAN study (Microbiome Shifts in Adolescent Anorexia Nervosa) NCT02962726. The aim of this study is to evaluate the effect of starvation and recovery in adolescent anorexia nervosa patients in regard to microbiome activity and composition and to elucidate potential connections between weight gain, depression and other comorbidities, further to capture hormone levels and inflammation parameters in a longitudinal design. Publication granted by Prof. Deserno, UK Aachen. Blutwerte Basis und zusätzliche Blutwerte Formular der MaAN Studie (Veränderungen des Mikrobioms bei adoleszenter Anorexia Nervosa) NCT02962726.

Emotional processing in healthy male volunteers treated with GSK424887 NCT01424384 - Vital Signs and ECG - Follow up

- 21.08.18 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache

Itemgruppen: Vital signs, 12 lead ECG

Study ID: 105012 Clinical Study ID: NSS105012 Study Title: Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01424384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK424887 Trade Name: Citalopram Study Indication: Depressive Disorder and Anxiety Disorders

Early Withdrawal GSK Rosiglitazone Alzheimer's disease 100468

- 25.07.17 - 1 Formular, 12 Itemgruppen, 18 Datenelemente, 1 Sprache

Itemgruppen: Central Laboratory Instructions, Visit Information, Investigator Instructions, Vital Signs, Central Laboratory, Pregnancy Test, Concomitant Medication, Adverse Event, Physical Examination, Pedal Oedema, Rating Scale Instructions, End of Visit Reminder

Study ID: 100468 Clinical Study ID: AVA100468 Study Title: An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Avandia XR,Rosiglitazone XR,Avandia Study Indication: Alzheimer's Disease Early Withdrawal

Stichworte

Inhaltsverzeichnis

Ausgewählte Datenmodelle